Eye Opener: Kavanaugh accuser says she’ll testify next week on own terms

FAN Editor
CBSN

<![CDATA[
article.article .article-lead-image { background-size: cover; background-position: unset; background-repeat: no-repeat; height: 500px; box-shadow: 0 100px 100px rgba(0,0,0,0.05); margin-bottom: 30px; display: block !important;}
.evening-news .module-rem h2.title,
.evening-news .module>.title,
.evening-news .listing-full-focus-with-label .items .item>.label,
.evening-news .listing-full-lead-media .items .item>.label,
.evening-news .module-listing.module-basic .module-heading.title,
.evening-news .module .module-heading.title { font-family: “futura-pt”,Helvetica,Roboto,sans-serif;
}
.mobile [data-role=”content”] > .container::before { display: none;
} ]]]]>
]]>
<![CDATA[

]]>
<![CDATA[

]]>
<![CDATA[

]]>
<![CDATA[

]]>

Free America Network Articles

Leave a Reply

Next Post

Is Pot Stock GW Pharmaceuticals Undervalued?

GW Pharmaceuticals (NASDAQ: GWPH) is on the cusp of shaking up the U.S. epilepsy treatment market. The medical marijuana company won FDA approval for Epidiolex’s use in rare childhood-onset epilepsy over the summer and it should become commercially available to patients as soon as a decision is made on scheduling […]

You May Like